Jefferies Defends Epizyme (EPZM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Jefferies Defends Epizyme (EPZM)
December 18, 2019 11:48 AM EST
FDA AdCom positive on Epizyme (NASDAQ: EPZM) Tazemetostat. 11 Yes votes that the benefits outweigh the risks. 0 No votes. (shares halted)
...
More
December 16, 2019 9:23 AM EST
Today's Pre-Open Movers
Axsome Therapeutics, Inc. (NASDAQ: AXSM) 78.5% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary endpoint and rapidly and significantly improved symptoms of depression in the GEMINI Phase 3 trial in major depressive disorder (MDD). The GEMINI study was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, in which 327 adult patients with confirmed moderate to severe MDD were randomized to treatment with either AXS-05 (dextromethorphan/bupropion modulated delivery tablet) or placebo once daily for the first 3 days and twice... More
December 16, 2019 8:24 AM EST
Epizyme (NASDAQ: EPZM) on watch with FDA briefing documents released (LINK)
...
More
